Angiochem to Present at Stifel Nicolaus 2011 Healthcare Conference

MONTREAL--(BUSINESS WIRE)-- Angiochem, Inc., a clinical stage biotechnology company, today announced that Jean Paul Castaigne, MD, President and CEO is scheduled to present at the Stifel Nicolaus 2011 Healthcare Conference at 2:05 p.m. ET on Wednesday, September 7, 2011, at the Four Seasons Hotel, Boston.

About Angiochem

Angiochem is a clinical-stage biotechnology company discovering and developing new breakthrough drugs that are leveraging the LRP-1 mediated pathway to cross the blood-brain barrier (BBB) to treat brain diseases. These new Engineered Peptide Compounds (EPiC) have the potential to address significant medical needs, many of which cannot be effectively addressed due to the fundamental physiological challenge the blood-brain barrier presents for therapeutic intervention. Angiochem is developing a deep and broad product pipeline, including small molecules and biologics, for the potential treatment of a wide range of CNS diseases, including brain cancer, neurodegenerative and metabolic diseases, pain, and many others. Founded in 2003, Angiochem maintains headquarters in Montreal, Canada. For additional information about the Company, please visit http://www.angiochem.com.



CONTACT:

Media Contact:
The Yates Network
Gina Nugent, 617-460-3579
or
Business Development Contact:
Angiochem, Inc.
Catherine Gagnon, 514-788-7800 x204

KEYWORDS:   North America  Canada

INDUSTRY KEYWORDS:   Health  Biotechnology  Clinical Trials  Mental Health  Pharmaceutical  Other Health  Research  Science

MEDIA:

Suggested Articles

Xcovery's ALK inhibitor shrank tumors in 75% of lung cancer patients, compared to 67% for Pfizer's Xalkori, the first FDA-approved drug of that class.

The FDA accepted the regulatory filing for Biogen's once-failed Alzheimer's drug, aducanumab, with plans to decide its fate by March 7, 2021.

Alexion named a chief diversity officer, while COVID-19 vaccine player has two new members of its C-suite.